{"id":"W4410983248","doi":"10.1016/j.eururo.2025.05.017","title":"Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node–only Disease","year":2025,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Merck KGaA; Merck","keywords":"Medicine; Metastatic Urothelial Carcinoma; Avelumab; Hazard ratio; Internal medicine; Oncology; Lymph node; Clinical endpoint; Regimen; Carcinoma; Bladder cancer; Confidence interval; Randomized controlled trial; Urothelial carcinoma; Cancer; Pembrolizumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001444612,0.0006485877,0.001496056,0.0002453582,0.0002372791,0.001214094,0.0005665784,0.0007740419,0.001806426],"category_scores_gemma":[0.001492145,0.0002757335,0.002078546,0.0003907478,0.0005875573,0.00106639,0.0004079158,0.002319192,0.0003364347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006549759,"about_ca_system_score_gemma":0.0004956496,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001005865,"about_ca_topic_score_gemma":0.002532247,"domain_scores_codex":[0.9995054,0.0002349925,0.00002727798,0.00008427078,0.00004139289,0.0001067068],"domain_scores_gemma":[0.9992822,0.000194084,0.000195074,0.00006989604,0.0000345204,0.0002241645],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8467476,0.004119803,0.03693068,0.001695268,0.009921158,0.0002440909,0.000216194,0.003596596,0.009257387,0.0004598401,0.005759324,0.08105193],"study_design_scores_gemma":[0.509882,0.1398342,0.3080933,0.0005479055,0.01861884,0.0007972153,0.0004855104,0.005415147,0.00335507,0.001327269,0.01144735,0.0001962938],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886068,0.008494287,0.0001468629,0.0004908803,0.0001414677,0.00006991936,0.0008783449,0.00002498531,0.001146623],"genre_scores_gemma":[0.9925846,0.003065537,0.000198677,0.0005365851,0.0001748443,0.0000879819,0.002113093,0.00001379048,0.001224795],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001806426,"threshold_uncertainty_score":0.007639885,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01922691504164975,"score_gpt":0.2750866555957063,"score_spread":0.2558597405540566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}